Nordic Nanovector CEO Luigi Costa indicated that the company, which is developing new ways to treat blood cancers, has seen increasing interest from potential buyers, as reported in NASDAQ.

• "We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that's for sure," Costa remarked, adding "if the already good data continues to be confirmed, I think the interest will grow."

• The chief executive suggested that Nordic Nanovector should also be ready to launch drugs independently or through partnership, saying the company will be "opportunistic about this."

• Nordic Nanovector is currently preparing a final test phase for its Betalutin drug candidate for the potential treatment of non-Hodgkin lymphoma.